echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Luye Pharma's Class 1 new drug Ansufaxine Hydrochloride Sustained-Release Tablets reached the preset end point in Phase III clinical trials

    Luye Pharma's Class 1 new drug Ansufaxine Hydrochloride Sustained-Release Tablets reached the preset end point in Phase III clinical trials

    • Last Update: 2021-04-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Luye Pharma announced that its self-developed new compound and a new class 1 chemical drug in China-Ansufacine Hydrochloride Sustained Release Tablets (LY03005) have reached the preset end point in the Phase III clinical trial in China.


    LY03005 is a serotonin-norepinephrine-dopamine triple reuptake inhibitor (SNDRI) for the treatment of depression.


    The results of this phase III clinical trial show that: LY03005 is safe and effective in treating depression and can comprehensively improve depression symptoms, especially in alleviating anhedonia, improving cognitive function and not affecting sexual function.


    The China Phase III clinical trial of LY03005 is a multi-center, randomized, double-blind, placebo-controlled study to verify the effectiveness and safety of LY03005 in the treatment of depression.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.